Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY® (piflufolastat F 18).
“Participating in a national conversation on improving cancer care is a great honor. We are being asked to reconsider how we address cancer from prevention through survivorship. It’s a huge undertaking, but a very exciting one. I’m delighted to be a part of it.” –Danelle Johnston, MSN, RN, ONN-CG, OCN
JONS is delighted to announce this new department to offer thought-provoking insights, address the impact of various forces in our culture on navigation, and reaffirm of the importance of navigation programs.